Promising therapy for relapsing multiple sclerosis
Links shared publicly online about this topic.
- 1,372total visits
Promising therapy for relapsing multiple sclerosis
View full resource at sciencedaily.com
Tags: Brain, Multiple Sclerosis, Scientist, Science
Most Recently Shared on February 18, 2010 at 7:28 pm By:
Experimental Pill May Ease Multiple Sclerosis Disability - Yahoo! News
news.yahoo.com — “From Yahoo! News: WEDNESDAY, March 14 (HealthDay News) -- Yet another orally taken medication shows some promise in preventing relapse and disability for people with relapsing-remitting multiple sclerosis, a new report suggests.” View full resource at news.yahoo.com
Most Recently Shared on March 15, 2012 at 12:08 am By:
Experimental Pill May Ease Multiple Sclerosis Disability: WEDNESDAY, March 14 (HealthDay News) -- Yet another or... http://t.co/3X5qwVc2
MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients
news-medical.net — “Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE (glatiramer acetate injection) experienced significantly increased magnetization transfer ratio.” View full resource at news-medical.net
Most Recently Shared on January 4, 2012 at 2:19 pm By:
News-Medical.Net Health News and Oncology
Oncology News: MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients: Research... http://t.co/5nsQ0ex9
Multiple Sclerosis Drug Shows Promise In Late-Stage Trial | ThirdAge
thirdage.com — “A multiple sclerosis drug has been shown to reduce relapse rates by nearly 50 percent and lower the risk of worsening of disabilities by over 40 percent in a late-stage trial.” View full resource at thirdage.com
Most Recently Shared on November 14, 2011 at 7:01 pm By:
Multiple Sclerosis Drug Shows Promise In Late-Stage Trial http://t.co/RFgdrhNe
New Multiple Sclerosis Therapy Promising in Early Trial - Drugs.com MedNews
drugs.com — “Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary” View full resource at drugs.com
Most Recently Shared on November 1, 2011 at 5:24 pm By:
New Multiple Sclerosis Therapy Promising in Early Trial - http://t.co/ivm3Zqtk
New Multiple Sclerosis Therapy Promising in Early Trial - iVillage
ivillage.com — “TUESDAY, Nov. 1 (HealthDay News) -- Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary research suggests. The errant behavior of the” View full resource at ivillage.com
Most Recently Shared on November 1, 2011 at 3:49 pm By:
New Multiple Sclerosis Therapy Promising in Early Trial http://t.co/P1iK4691
Experimental MS Drug Shows Promise - iVillage
ivillage.com — “WEDNESDAY, Oct. 5 (HealthDay News) -- A new oral drug for relapsing forms of multiple sclerosis appears to reduce relapse rates and disability progression, according to the results of a so-called phase 3 trial. The experimental drug, terifluno” View full resource at ivillage.com
Most Recently Shared on October 8, 2011 at 7:25 pm By:
Experimental MS Drug Shows Promise http://ow.ly/6PAxe
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate AndDisability Progression
medicalnewstoday.com — “Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The” View full resource at medicalnewstoday.com
Most Recently Shared on October 8, 2011 at 8:05 am By:
MNT Pharma News Health News and Pharma
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate A... http://mnt.to/42bg
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity - Drugs.com MedNews
drugs.com — “- Findings from Two-Year Pivotal Phase III TEMSO Trial Published today in The New England Journal of Medicine - Paris, France - October 5, 2011 - Sanofi (EURONE” View full resource at drugs.com
Most Recently Shared on October 6, 2011 at 3:13 pm By:
Drugs and Devices OW OW Health
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio) Significantly Reduced Relapse Rate... http://t.co/6iGKI9Wl #drug
Investigational Oral MS Therapy Teriflunomide Reduced Relapse Rate, Disability Progression & Disease Activity http://t.co/r7w8tXad
en.sanofi.com — “Investigational Oral MS Therapy Teriflunomide Reduced Relapse Rate, Disability Progression & Disease Activity http://t.co/r7w8tXad” View full resource at en.sanofi.com
Most Recently Shared on October 6, 2011 at 2:04 pm By:
Investigational Oral MS Therapy Teriflunomide Reduced Relapse Rate, Disability Progression & Disease Activity http://t.co/r7w8tXad
UCI study shows promise of metabolic therapy for autoimmune diseases
news-medical.net — “A glucosamine-like dietary supplement suppresses the damaging autoimmune response seen in multiple sclerosis, according to a UC Irvine study.” View full resource at news-medical.net
Most Recently Shared on October 1, 2011 at 7:38 am By:
Genetics News: UCI study shows promise of metabolic therapy for autoimmune diseases: A glucosamine-like dietary ... http://t.co/4PasChtN
Study looks at early liberation therapy of MS patients - QualityPoint Technologies
qualitypointtech.net — “A small study of 15 patients with multiple sclerosis suggests those who get balloon angioplasty treatment earlier have fewer disease relapses, and may have decreased brain volume that could indicate a lessening of inflammation in their brains. (Source: CTV Health)” View full resource at qualitypointtech.net
Most Recently Shared on August 13, 2011 at 2:00 am By:
Study looks at early liberation therapy of MS patients: A small study of 15 patients with multiple sclerosis sugge... http://t.co/mX1yeAU
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial : The Lancet Neurology
thelancet.com — “Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. By - Prof Per Soelberg Sorensen MD, ...” View full resource at thelancet.com
Most Recently Shared on July 27, 2011 at 11:02 pm By:
Edgar Avalos, MD Neurology and Health Group
No beneficial effect of simvastatin as add-on therapy to interferon beta-1a http://t.co/Uk7KtUc
Neurology Article | Multiple Sclerosis
mdlinx.com — “Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial : The Lancet Neurology” View full resource at mdlinx.com
Most Recently Shared on July 27, 2011 at 6:23 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN... http://bit.ly/r6OKbK #neuro
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial : The Lancet Neurology
thelancet.com — “Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. By - Prof Per Soelberg Sorensen MD, ...” View full resource at thelancet.com
Most Recently Shared on July 11, 2011 at 5:00 am By:
Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to .... http://bit.ly/mUbJIn
Dextromethorphan shows promise in Multiple Sclerosis study -Sacramento California News including Folsom, Elk Grove
sacramentotoday.net — “Dextromethorphan shows promise in Multiple Sclerosis study. (SACRAMENTO, Calif.) - A drug widely used in over-the-counter cough medicines appears to protect against symptoms of multiple sclerosis, a finding that could offer a new and inexpensive therapy for a condition with few effective treatment options, a study by UC Davis researchers has found.” View full resource at sacramentotoday.net
Most Recently Shared on July 8, 2011 at 10:36 am By:
Dextromethorphan shows promise in Multiple Sclerosis study: (SACRAMENTO, Calif.) - A drug widely used in over-th... http://bit.ly/qGl2VX
Advertisement
